Stephen Galli Net Worth

Stephen Galli biography

Dr. Stephen J. Galli M.D. serves as Independent Director of the Company. Dr. Galli has been a Professor of Pathology and of Microbiology & Immunology and the Mary Hewitt Loveless, M.D., Professor, Stanford University School of Medicine, Stanford, California since February 1999. He served as Chair of the Department of Pathology at Stanford University School of Medicine from 1999 to 2016. Before joining Stanford, he was on the faculty of Harvard Medical School. He holds 14 U.S. patents and has over 400 publications. He is past president of the American Society for Investigative Pathology, past president of the Collegium Internationale Allergologicum, and current president of the Pluto Club (Association of University Pathologists). In addition to receiving several awards for his research, he was recognized with the 2010 Stanford University President’s Award for Excellence through Diversity for his recruitment and support of women and underrepresented minorities at Stanford University. He received his B.A. degree in biology, magna cum laude, from Harvard College in 1968 and his M.D. degree from Harvard Medical School in 1973 and completed a residency in anatomic pathology at the Massachusetts General Hospital in 1977. Dr. Galli has been selected to serve on the Company’s Board of Directors because of his qualifications as a professor and physician, and his specialized expertise as a pathologist.

How old is Stephen Galli?

Stephen Galli is 73, he's been the Independent Director of Atossa Therapeutics Inc since 2011. There are no older and 8 younger executives at Atossa Therapeutics Inc.

What's Stephen Galli's mailing address?

Stephen's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC.,, 107 SPRING STREET, SEATTLE, WA, 98104.

Insiders trading at Atossa Therapeutics Inc

Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over $114,740 worth of Atossa Therapeutics Inc stock and bought 274,300 units worth $204,285 . The most active insiders traders include Gregory L Weaver, Steven C Quay и Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of $38,260. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth $44,250.

What does Atossa Therapeutics Inc do?

atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.

Atossa Therapeutics Inc executives and stock owners

Atossa Therapeutics Inc executives and other stock owners filed with the SEC include:

• Steven Quay,
  Chairman of the Board, President, Chief Executive Officer
• Kyle Guse,
  Chief Financial Officer, General Counsel, Secretary
• Dr. Steven C. Quay,
  Chairman, CEO & Pres
• Kyle Guse CPA, Esq., CPA,
  CFO, Gen. Counsel & Sec.
• Shu-Chih Chen,
  Director
• Gregory Weaver,
  Independent Director
• Scott Gordon,
  IR Contact Officer
• Richard Steinhart,
  Independent Director
• H. Lawrence Remmel,
  Independent Director
• Stephen Galli,
  Independent Director
• Janet Rose Rea MSPH, RAC,
  Sr. VP of Regulatory, Quality & Clinical Affairs
• Delly Behen P.H.R.,
  VP of Admin. & HR
• Heather Rees,
  VP of Fin. & Accounting
• Janet Rose Rea,
  Sr. VP of Regulatory, Quality & Clinical Affairs
• Scott Youmans,
  Chief Operating Officer
• Heather Rees,
  SVP, Finance and Accounting
• Jonathan Finn,
  
• Tessa Cigler,
  
• Christopher S. Destro,
  Sr. VP, Sales and Marketing
• John Barnhart,
  Director
• John E Sawyer,
  See Remarks
• Peter J. Carbonaro,
  Sr. Vice President, Operations
• Ben R Chen,
  Sr. VP of Glob. Reg. Affairs
• Alexander D Cross,
  Director